Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.62 |
| ▸ | CASR | P41180 | 6/20 | 0.53 |
| ▸ | ACACB | O00763 | 1/20 | 0.47 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.45 |
| ▸ | MLYCD | O95822 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | DHFR | P00374 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14636981 | 0.85 | ABL1 (0.47) | NOTUMCASRGPR139ABL1 | |
| SCHEMBL12301329 | 0.82 | KMT2A (0.53) | FFAR4 | |
| SCHEMBL2853626 | 0.78 | NOTUM (0.64) | NOTUMCASRACACBFFAR4CHRM4 | |
| SCHEMBL30596350 | 0.78 | NOTUM (0.64) | NOTUMCASRACACBFFAR4CHRM4 | |
| SCHEMBL31334501 | 0.76 | SMARCA2 (0.40) | NOTUMDHFR | |
| SCHEMBL22815763 | 0.76 | NOTUM (0.48) | NOTUMCASRFFAR4CHRM4ABL1 | |
| SCHEMBL31334193 | 0.76 | SMARCA2 (0.40) | NOTUMDHFR | |
| SCHEMBL6628944 | 0.74 | ALDH1A1 (0.53) | NOTUM | |
| SCHEMBL3060159 | 0.74 | NOTUM (0.59) | NOTUMCASRACACBFFAR4CHRM4 | |
| SCHEMBL8106701 | 0.73 | NOTUM (0.55) | NOTUMCASRACACBFFAR4MLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1757582-B1 | ARYLALKYLAMINES AND PROCESS FOR PRODUCTION THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-12-30 | — | — | EP | disclosed |
| US-8778628-B2 | Arylalkylamine compound and process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-07-15 | — | — | US | disclosed |
| US-8759387-B2 | Arylalkylamine compound and process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-06-24 | — | — | US | disclosed |
| US-8703721-B2 | Arylalkylamine compound and process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-04-22 | — | — | US | disclosed |
| US-8703721-B2 | Arylalkylamine compound and process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-04-22 | — | — | US | disclosed |
| US-20140080770-A1 | ARYLALKYLAMINE COMPOUND AND PROCESS FOR PREPARING THE SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-03-20 | — | — | US | disclosed |
| US-20140080770-A1 | ARYLALKYLAMINE COMPOUND AND PROCESS FOR PREPARING THE SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-03-20 | — | — | US | disclosed |
| US-8492111-B2 | Arylalkylamine compound and process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-07-23 | — | — | US | disclosed |
| US-8492111-B2 | Arylalkylamine compound and process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-07-23 | — | — | US | disclosed |
| US-8492111-B2 | Arylalkylamine compound and process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-07-23 | — | — | US | disclosed |
| US-8362274-B2 | Arylalkylamine compound and process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-01-29 | — | — | US | disclosed |
| US-20110218160-A1 | ARYLALKYLAMINE COMPOUND AND PROCESS FOR PREPARING THE SAME | MIYAZAKI HIROSHI | 2011-09-08 | — | — | US | disclosed |
| US-20110218160-A1 | ARYLALKYLAMINE COMPOUND AND PROCESS FOR PREPARING THE SAME | MIYAZAKI HIROSHI | 2011-09-08 | — | — | US | disclosed |
| US-20100249049-A1 | ARYLALKYLAMINE COMPOUND AND PROCESS FOR PREPARING THE SAME | MIYAZAKI HIROSHI | 2010-09-30 | — | — | US | disclosed |
| US-20100249049-A1 | ARYLALKYLAMINE COMPOUND AND PROCESS FOR PREPARING THE SAME | MIYAZAKI HIROSHI | 2010-09-30 | — | — | US | disclosed |
| US-20100249049-A1 | ARYLALKYLAMINE COMPOUND AND PROCESS FOR PREPARING THE SAME | MIYAZAKI HIROSHI | 2010-09-30 | — | — | US | disclosed |
| US-20070225296-A1 | Arylalkylamine Compound and Process for Preparing the Same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-09-27 | — | — | US | disclosed |
| US-20070225296-A1 | Arylalkylamine Compound and Process for Preparing the Same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-09-27 | — | — | US | disclosed |
| US-20070225296-A1 | Arylalkylamine Compound and Process for Preparing the Same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-09-27 | — | — | US | disclosed |
| EP-1757582-A1 | ARYLALKYLAMINES AND PROCESS FOR PRODUCTION THEREOF | TANABE SEIYAKU CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080770-A1 | ARYLALKYLAMINE COMPOUND AND PROCESS FOR PREPARING THE SAME | NAT1, INMT, ARSA | NOTUM 403/4885CASR 3976/4885ACACB 1919/4885 |
| US-20110218160-A1 | ARYLALKYLAMINE COMPOUND AND PROCESS FOR PREPARING THE SAME | CASR, CNR1, CNR2 | NOTUM 2981/4885CASR 1/4885ACACB 3981/4885 |
| US-20070225296-A1 | Arylalkylamine Compound and Process for Preparing the Same | CASR, CNR1, CNR2 | NOTUM 2981/4885CASR 1/4885ACACB 3981/4885 |
| US-20100249049-A1 | ARYLALKYLAMINE COMPOUND AND PROCESS FOR PREPARING THE SAME | CASR, CNR1, CNR2 | NOTUM 2981/4885CASR 1/4885ACACB 3981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.